Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Ariel Fund declined -0.66% in the quarter, falling shy of Russell 2500 Value and Russell 2500 Indices, which returned -0.26% ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

They invest in public stocks and bonds, and their clients are increasingly sensitive to costs. Their most popular products these days are passive index trackers with razor-thin fees, often just a few ...

The Aiken County Historical Museum will continue its Winter Lecture Series at 3 p.m. Sunday, Feb. 23. The program will be The ...

Hexaware Technologies debuted positively on the National Stock Exchange (NSE) on Wednesday, listing shares at a 5.3% premium ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Deal pros may be surveying the landscape for restaurant brands that are on the brink of Chapter 11. Plus: Family Dollar is ...